Factor XII Deficiency Acquired by Orthotopic Liver Transplantation: Case Report and Review of the Literature

Transplant Center, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
American Journal of Transplantation (Impact Factor: 5.68). 08/2006; 6(7):1743-5. DOI: 10.1111/j.1600-6143.2006.01363.x
Source: PubMed


Transmission of congenital clotting factor deficiencies after orthotopic liver transplantation is rare. There are published reports of liver donor-to-recipient transmission of protein C deficiency with dysfibrinogenemia, protein S, factor VII and factor XI deficiencies. We report a case of transmission of factor XII deficiency with liver transplantation in a patient with Budd-Chiari syndrome. There was a persistent elevation of the activated partial thromboplastin time (aPTT), but no evidence of bleeding while the patient was maintained on warfarin. The presence of a persistently abnormal aPTT may raise suspicion for the presence of a clotting factor deficiency; however, deficiencies of other clotting factors may not be readily apparent on routine blood tests performed in a donor. Being aware of the possibilities of transmission of these inherited deficiencies of coagulation factors will aid in their early detection and management in the transplant donor and recipient.

Full-text preview

Available from:
  • [Show abstract] [Hide abstract]
    ABSTRACT: In patients post organ transplantation, the underlying disorder necessitating the transplantation, as well as the transplantation itself, can both mask pre-existing haemostatic abnormalities or lead to them. Since the liver is the main production site for coagulation factors, orthotopic liver transplantation predestinates for acquiring or losing a genetically determined coagulation defect. In coagulation diagnostics, this may lead to a discrepancy between functional plasma tests and molecular biologic findings if these are gathered from nucleated cells of the peripheral blood, as is the standard. Due to the rareness of most defects and the lack of consequences in case of diagnosis of a more common coagulation disorder, no general screening before or after transplantation is required. Underlying diseases leading to liver transplantation as well as the actual transplantation must be considered when interpreting the findings.
    No preview · Article · Sep 2007 · Hamostaseologie
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the main advantages of liver transplantation (LT) has been to ­concentrate particular and rare liver diseases in a restricted number of ­centers. This policy has led to a much better understanding, diagnosis, and treatment of these, many times, difficult conditions. This chapter gives a comprehensive and updated review in relation to vascular liver diseases. It is without any doubt that hemangioma, angiosarcoma (AS), infantile hemangioendothelioma (IHE), epithelioid hemangioendothelioma (EHE), hemorrhagic hereditary telangiectasia (HHT), Budd-Chiari syndrome (BCS), and nodular regenerative hyperplasia (NRH) took really profit of the latest developments in the field of LT. Based on the worldwide transplant experience, diagnostic and therapeutic algorithm of these diseases very much improved. We now know that LT is absolutely contraindicated in case of AS; that LT is of great value in the treatment of EHE and HHT and that indications of LT for IHE, BCS, and NRH must be highly individualized. The second part of this chapter deals with particular features of hepatic and splanchnic vessels, which are of importance as well in the pre-LT as post-LT periods. These vascular modifications are important to know as well for the transplant physician and surgeon in order to make the transplant procedure successful. KeywordsVascular tumors – epithelioid hemangioendothelioma – infantile hemangioendothelioma-Hemangiosarcoma – nodular regenerative hyperplasia-Budd-Chiari syndrome-Hereditary hemorrhagic telangiectasia-Splanchnic venous thrombosis-Portal vein thrombosis-Caval ­thrombosis – ­cavoportal transposition – TIPSS – thrombectomy-Arterial thrombosis – coagulation – liver transplantation
    No preview · Chapter · Dec 2010
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pseudoxanthoma elasticum (PXE) is thought to be a metabolic disorder resulting from mutations in the gene encoding the cellular transporter, ABCC6, which is primarily expressed in liver and kidney. We encountered 3 patients who developed clinical and histopathological evidence of PXE after liver transplantation, suggesting that PXE could have been acquired from the transplanted organ. We sought to delineate the clinical features and screen each patient and samples of donor liver for mutations in the ABCC6 gene. Each patient underwent full clinical examination, skin biopsy, and ophthalmologic examination, and whole genome sequencing using standard techniques. Fixed samples of donor liver tissue were available for mutation analysis in two patients and of donor kidney tissue in one. All 3 patients had unequivocal clinical and histopathologic evidence of PXE. No patient (or family member available for screening) had evidence of mutations in ABCC6. Neither liver specimen nor the single available kidney specimen showed evidence of mutations in ABCC6. Liver tissue was not available from one patient and DNA was of poor quality in another, resulting in limited screening. Genetic testing does not detect ABCC6 mutations in 10% of patients with confirmed PXE. Although we were unable to demonstrate ABCC6 mutations in limited screening of fixed donor livers, the absence of any PXE mutations in the affected patients, the timing of onset of PXE, and the known acquisition of other metabolic disorders and coagulopathies from donor livers suggest that PXE was likely acquired via liver transplantation.
    Full-text · Article · Mar 2011 · Journal of the American Academy of Dermatology
Show more